NCT00984815View on ClinicalTrials.gov

Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
OsteoarthritisRheumatoid ArthritisChronic Low Back PainChronic Regional Pain SyndromeChronic Soft Tissue Pain
Interventions
DRUG

HZT-501

Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day

Trial Locations (4)

16635

Altoona Center for Clinical Research Altoona Arthritis, Duncansville

60053

Illinois Bone & Joint Institute, Morton Grove

75231

Metroplex Clinical Research Center, Dallas

60612-7323

University of Illinois Medical Center, Department of Medicine, Chicago

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00984815 - Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment | Biotech Hunter | Biotech Hunter